| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
As a synthetic porphyrin, TTP does not have specific biological receptors as its primary targets. However, it is used in photodynamic therapy for treating cancer, where its ability to produce reactive oxygen species upon light activation makes it effective in targeting and destroying cancer cells. The compound also serves as a photosensitizer in dye-sensitized solar cells. In biological research, TTP is used as a fluorescent probe due to its strong fluorescence properties. Its ability to generate reactive oxygen species upon light activation is the basis for its potential therapeutic applications.
|
|---|---|
| ln Vitro |
In life science research, 5,10,15,20-Tetrakis(p-tolyl)porphyrin is a biochemical reagent that can be utilized as an organic substance or biological material.
In vitro, TTP has been investigated for its applications in photodynamic therapy, where it produces reactive oxygen species upon light activation to destroy cancer cells. The compound also serves as a fluorescent probe for biological imaging due to its strong fluorescence properties. As a catalyst, it improves reaction rates and selectivity in various chemical reactions. TTP is also used in materials science for developing organic semiconductors. Its unique electronic properties make it valuable for both biological and materials science applications. Cellular assays typically evaluate its photodynamic activity or fluorescence properties. |
| ln Vivo |
In vivo, TTP has been explored for photodynamic therapy applications in treating cancer. The compound's ability to produce reactive oxygen species upon light activation makes it potentially effective for targeted cancer therapy. However, TTP is primarily a research compound and is not an approved therapeutic agent. Its applications in vivo would depend on appropriate formulation and light delivery to target tissues. The compound is classified for research use only and is not intended for human therapeutic applications without further development.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for TTP are not typically performed, as it is primarily used as a photosensitizer and catalyst rather than a receptor-targeting agent. However, its photodynamic activity can be evaluated in cell-free systems by measuring reactive oxygen species production upon light activation. A typical assay involves dissolving TTP in an appropriate solvent (e.g., DMSO) and diluting to working concentrations in buffer. The compound is irradiated with light at specific wavelengths (typically 400-700 nm). Reactive oxygen species production is measured using fluorescent probes such as singlet oxygen sensor green or DCFH-DA. The efficiency of photosensitization is calculated from dose-response curves.
|
| Cell Assay |
Cellular assays for TTP typically evaluate its photodynamic activity and fluorescence properties. A standard protocol involves culturing cancer cell lines (e.g., HeLa, MCF-7) in growth medium at 37°C with 5% CO₂. Cells are incubated with varying concentrations of TTP (typically 0.1-10 μM) for 4-24 hours. After incubation, cells are irradiated with light at specific wavelengths for varying durations. Cell viability is assessed using MTT, CCK-8, or Live/Dead staining. Fluorescence imaging can be performed to visualize cellular uptake and localization of the compound. IC₅₀ values for photodynamic activity are calculated from dose-response curves.
|
| Animal Protocol |
In vivo animal studies for TTP typically evaluate its photodynamic therapy efficacy in tumor-bearing mouse models. A common protocol involves subcutaneous implantation of cancer cells into immunodeficient mice. Once tumors reach appropriate size (approximately 100-200 mm³), animals are administered TTP via intravenous injection at doses ranging from 1-10 mg/kg. After a suitable drug-light interval (typically 4-24 hours), tumors are irradiated with light at specific wavelengths. Tumor volume and body weight are monitored regularly. Endpoints include tumor growth inhibition, survival analysis, and histopathological examination of tumor tissues.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for TTP is limited, as it is primarily a research compound. The compound has a molecular weight of 670.86 g/mol and is a purple solid at room temperature. It is stored at room temperature. As a porphyrin, TTP is expected to have high lipophilicity and strong protein binding. The compound's large molecular size and hydrophobic nature suggest limited oral bioavailability and potential for accumulation in tissues. Specific ADME data is not available in the public literature.
|
| Toxicity/Toxicokinetics |
Toxicological data for TTP is limited, as it is primarily a research compound. The compound is classified for research use only and is not intended for human or veterinary applications. Standard safety precautions include handling with appropriate personal protective equipment (gloves, lab coat, safety goggles) in a well-ventilated area. The compound is not classified as a hazardous material (No Hazmat). Acute toxicity data is not readily available in the public literature. As with all research chemicals, appropriate laboratory safety practices should be followed. No specific LD₅₀ values or detailed toxicological profiles are available in the public domain.
|
| Additional Infomation |
5,10,15,20-Tetrakis(p-tolyl)porphyrin (TTP, CAS 14527-51-6) is a synthetic porphyrin with the molecular formula C₄₈H₃₈N₄. It is used in photodynamic therapy research for cancer treatment, as a photosensitizer in solar cells, as a fluorescent probe for biological imaging, and as a catalyst in organic synthesis. The compound is classified as a research-use-only compound not intended for diagnostic or therapeutic purposes. It is available from multiple commercial suppliers in various pack sizes. No clinical trials or approved drug status exist for this compound as it is not a therapeutic agent. Its applications are limited to research and materials science.
|
| Molecular Formula |
C48H38N4
|
|---|---|
| Molecular Weight |
670.84
|
| Exact Mass |
670.31
|
| CAS # |
14527-51-6
|
| PubChem CID |
135401992
|
| Appearance |
Pale purple to purple solid powder
|
| Density |
1.207g/cm3
|
| Melting Point |
300ºC
|
| Index of Refraction |
1.673
|
| LogP |
8.099
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
52
|
| Complexity |
953
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1([H])C2C([H])=C([H])C1=C(C1C([H])=C([H])C(C([H])([H])[H])=C([H])C=1[H])C1C([H])=C([H])C(=C(C3C([H])=C([H])C(C([H])([H])[H])=C([H])C=3[H])C3=C([H])C([H])=C(C(C4C([H])=C([H])C(C([H])([H])[H])=C([H])C=4[H])=C4C([H])=C([H])C(C=2C2C([H])=C([H])C(C([H])([H])[H])=C([H])C=2[H])=N4)N3[H])N=1 |c:30,75,t:8,68|
|
| InChi Key |
SFQNUQLWBBZIOZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C48H38N4/c1-29-5-13-33(14-6-29)45-37-21-23-39(49-37)46(34-15-7-30(2)8-16-34)41-25-27-43(51-41)48(36-19-11-32(4)12-20-36)44-28-26-42(52-44)47(40-24-22-38(45)50-40)35-17-9-31(3)10-18-35/h5-28,49,52H,1-4H3
|
| Chemical Name |
5,10,15,20-tetrakis(4-methylphenyl)-21,23-dihydroporphyrin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4907 mL | 7.4533 mL | 14.9067 mL | |
| 5 mM | 0.2981 mL | 1.4907 mL | 2.9813 mL | |
| 10 mM | 0.1491 mL | 0.7453 mL | 1.4907 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
